Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrology-Peritoneal Dialysis Consensus Workshop Report

Introduction: Peritoneal dialysis (PD)-related peritonitis is one of the leading causes of discontinuation of PD and is considered a critically important outcome for patients on PD. However, there is no universally accepted method of measuring this outcome in clinical trials.
Methods: We convened an online consensus workshop to establish a core outcome measure for PD-related peritonitis in clinical trials.
Results: A total of 53 participants, including 18 patients and caregivers, from 12 countries engaged in breakout discussions in this workshop. Transcripts were analyzed thematically. We identified the following 3 themes: (i) feasibility and applicability across diverse settings, which reflected the difficulty with implementing laboratory-based measures in resource-limited environments; (ii) ensuring validity, which included minimizing false positives and considering the specificity of symptoms; and (iii) being meaningful and tangible to patients, which meant that the measure should be easy to interpret, reflect the impact that symptoms have on patients, and promote transparency by standardizing the reporting of peritonitis among dialysis units.
Conclusion: A core outcome measure for PD-related peritonitis should include both symptom-based and laboratory-based criteria. Thus, the International Society for Peritoneal Dialysis (ISPD) definition of peritonitis is acceptable. However, there should be consideration of reporting suspected peritonitis in cases where laboratory confirmation is not possible. The measure should include all infections from the time of catheter insertion and capture both the rate of infection and the number of patients who remain peritonitis free. A core outcome measure with these features would increase the impact of clinical trials on the care and decision-making of patients receiving PD.

Aim

To identify the essential features of a core outcome measure for PD-related peritonitis, the most serious infection.

Contributors

Jenny I. Shen, Yeoungjee Cho, Karine E. Manera, Fiona Brown, Jie Dong, Muthana Al Sahlawi, Rafael G. Acevedo, Htay Htay, Yasuhiko Ito, Talerngsak Kanjanabuch, Sharon J. Nessim, Grace Ngaruiya, Beth Piraino, Cheuk-Chun Szeto, Isaac Teitelbaum, Noa Amir, Jonathan C. Craig, Amanda Baumgart, Andrea M. Gonzalez, Nicole Scholes-Robertson, Andrea K. Viecelli, Martin Wilkie, Allison Tong and Jeffrey Perl, on behalf of the SONG-PD Infection Workshop Investigators.

Publication

Journal: Kidney international reports
Volume: 7
Issue: 8
Pages: 1737 - 1744
Year: 2022
DOI: 10.1016/j.ekir.2022.05.020

Further Study Information

Current Stage: Completed
Date:
Funding source(s): YC is supported by a National Health and Medical Research Council Early Career Fellowship (1126256). TK is supported by the National Research Council of Thailand (156/2560) and Rachadaphiseksompot Endorsement Fund (CU-GRS_60_12_30_05), Chulalongkorn University, Thailand. JP reports receiving grants from the Agency for Healthcare Research and Quality. JIS is supported by grant K23DK103972 from the National Institutes of Health—National Institute of Diabetes and Digestive and Kidney Diseases. AT is supported by a National Health and Medical Research Council Investigator Award (1197324). NSR is supported by a National Health and Medical Research Council Postgraduate Scholarship (ID1190850). AKV is supported by a National Health and Medical Research Council Emerging Leadership Investigator Grant (1196033).


Health Area

Disease Category: Infectious disease

Disease Name: peritonitis

Target Population

Age Range: Unknown

Sex: Either

Nature of Intervention: Surgery

Stakeholders Involved

- Clinical experts
- Consumers (patients)
- Other
- Policy makers
- Researchers

Study Type

- Recommendations for outcome measures (measurement/how)

Method(s)

- Semi structured discussion

The SONG-PD PD-Related Infection Consensus Workshop was held on September 23, 2020, to establish a core outcome measure for PD-related infection.